Hostname: page-component-848d4c4894-jbqgn Total loading time: 0 Render date: 2024-06-21T12:49:40.887Z Has data issue: false hasContentIssue false

When Does an Illness Begin: Genetic Discrimination and Disease Manifestation

Published online by Cambridge University Press:  01 January 2021

Extract

Congress passed the Genetic Information Nondiscrimination Act of 2008 (GINA) in order to remove a perceived barrier to clinical genetic testing. By banning health insurance companies and employers from discriminating against an individual based on his or her genetic information, legislators hoped that patients would be encouraged to seek genetic testing that could improve health outcomes and provide opportunities for preventive measures. Their explicit legislative goal was to fully protect the public from discrimination and allay their concerns about the potential for discrimination, thereby allowing individuals to take advantage of genetic testing, technologies, research, and new therapies.

However, GINA left a number of issues unresolved, most notably failing to define the concept of disease manifestation. GINA was structured such that it only provides protection against misuse of genetic information up until the point when an individual's disease has manifested. It protects an individual with a genetic predisposition for a disease, but not an individual actively suffering from that disease.

Type
Independent
Copyright
Copyright © American Society of Law, Medicine and Ethics 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Genetic Information NonDiscrimination Act, § (2008).Google Scholar
29 U.S.C.A. § 1182(a)(3)(B) (2008); 42 U.S.C.A. § 2000ff-9 (2008).Google Scholar
Note: An individual's genetic information is always protected under GINA. However any information about an individual's manifested condition or current symptoms is not protected. For example, if an individual has a family history of heart disease, this fact would be protected, but the individual's current high blood pressure is not.Google Scholar
Green, E. D. Guyer, M. S., and the National Human Genome Research Institute, “Charting a Course for Genomic Medicine from Base Pairs to Bedside,” Nature 470, no. 7333 (2011): 204213.CrossRefGoogle Scholar
Genetic Information Nondiscrimination Act (GINA) of 2008Google Scholar
Rothstein, M., “GINA, the ADA, and Genetic Discrimination in Employment,” Journal of Law, Medicine & Ethics 36, no. 4 (2008): 837840.CrossRefGoogle Scholar
Annas, G. J. Roche, P. Green, R. C., “GINA, Genism, and Civil Rights,” Bioethics 22, no. 7 (November 7, 2008): iiiv, atiii.CrossRefGoogle Scholar
Patient Protection and Affordable Care Act, Public Law 111–148 (2010).Google Scholar
Vorhaus, D., “Is the Genetic Rights Movement Picking Up Steam?” Genomic Law Report, March 16, 2011, available at <http://www.genomicslawreport.com/index.php/2011/03/16/is-the-genetic-rights-movement-picking-up-steam/>(last visited September 6, 2012).(last+visited+September+6,+2012).>Google Scholar
California Senate Bill No. 559, Introduced by Senator Padilla, February 17, 2011, available at <http://www.leginfo.ca.gov/pub/11–12/bill/sen/sb_0551–0600/sb_559_bill_20110217_introduced.pdf>(last visited September 6, 2012).(last+visited+September+6,+2012).>Google Scholar
See Rothstein, supra note 6.Google Scholar
EEOC Guidance, Section 902 Definition of the Term Disability. (Note: While the ADAAA regulations altered much of the Section 902 definition guidance, those regulations did not address genetic information).Google Scholar
McDevitt, W. J., “I Dream of GINA: Understanding the Employment Provisions of the Genetic Information Nondiscrimination Act of 2008,” Villanova Law Review 54, no. 91 (2009): 91116, at 104.Google Scholar
See Rothstein, supra note 6.Google Scholar
There are two federal statutes that include the concept of manifestation, the Wartime Disability Compensation Act (WDCA), 38 U. S. C. § 1110 (1998), and the National Childhood Vaccine Act (NCVA), 42 U.S.C.A. § 300aa-2, et. seq. (2003). The WDCA introduces a complicated concept of manifestation without ever defining what events or symptoms make a disease manifest. Under the WDCA, a disease is considered “incurred in or aggravated by” service in the military if it becomes “manifest to a degree of 10 percent” within a certain time period after the service. The statute does not include a discussion of what it means to have a disease manifest to a certain percentage and therefore lacks guidance in GINA analysis. Although this was researched, no cases interpreting the WDCA were found. The NCVA also introduces the concept of manifestation without providing a definition within the statute. The NCVA allows individuals to recover compensation for vaccine related injury or death. Section §300aa-11(c)(1)(C)(i) permits individuals to receive compensation for illnesses, disabilities, injuries, or conditions that manifested within the time period set forth in an accompanying Vaccine Injury Table.Google Scholar
Cardamone v. Allstate Ins. Co., 364 N.E.2d 460, 462 (Ill. App. 1977).Google Scholar
Id., at463.Google Scholar
648 So.2d 237 (1994).Google Scholar
Life General Sec. Ins. Co. v. Cook, 648 So.2d 237 (1994).Google Scholar
Cardamone v. Allstate Ins. Co., 364 N.E.2d 460, 462 (Ill. App. 1977).Google Scholar
574 F.3d 230, 236 (3rd Cir. 2009).Google Scholar
Id., at 232.Google Scholar
Id., at 235.Google Scholar
Tillman v. Lykes Brothers Steamship Company, 732 F.Supp. 1402, 1405 (S.D. Texas 1990).Google Scholar
574 F.3d 230, 236 (3rd Cir 2009).Google Scholar
732 F.Supp. 1402, 1404.Google Scholar
Id., at1405.Google Scholar
Wartime Disability Compensation Act (WDCA), 38 U. S.C. § 1110; Supra note 10.Google Scholar
Doroshow v. Hartford Life and Accident Insurance Company, 574 F.3d 230, 235 (3rd Cir. 2009).Google Scholar
344 Mass. 71, 74 (Mass. 1962).Google Scholar
210 N.W.2d 647, 648 (Supreme Court of Iowa, 1973).Google Scholar
Id., at 651.Google Scholar
344 Mass. 71, 74 (Mass. 1962), quoting Grain Handling Co., Inc. v. Sweeney, 102 F.2d 464, 466 (2nd Cir.).CrossRefGoogle Scholar
Mutual Hospital Ins., Inc. v. Klapper, 153 Ind. App. 555, 560 (Ind. App.1972).Google Scholar
See Rothstein, supra note 6.Google Scholar
E.g., 29 U.S.C.A. § 1182(a)(3)(B) (2008).CrossRefGoogle Scholar
29 U.S.C.A. § 1191b(d)(6)(A)(iii) (2008).Google Scholar
29 U.S.C.A. § 1191b(d)(7)(B)(ii) (2008).Google Scholar
42 U.S.C.A. § 2000ff-9.Google Scholar
29 C.F.R. § 1635.3(g) (2011); The most recent health insurance regulations have a similar definition of manifestation. 26 C.F.R. §54.9802–3T(a)(6)(i) (2009).Google Scholar
Hemochromatosis is a genetic disease that causes iron levels to build up in the body; without treatment, this can lead to organ damage or failure.Google Scholar
29 CFR § 1635.3(g); 26 CFR 54.9802–3T(a)(6)(i).Google Scholar
Baruch, S., “Your Genes Aren't Covered for That: One Year Later, Gaps in Genetic Discrimination Legislation Reveal the Challenges Ahead,” Science Progress (2009), available at <http://www.scienceprogress.org/2009/06/gina-challenges/>(last visited September 6, 2012).(last visited September 6, 2012).' href=https://scholar.google.com/scholar?q=Baruch,+S.,+“Your+Genes+Aren't+Covered+for+That:+One+Year+Later,+Gaps+in+Genetic+Discrimination+Legislation+Reveal+the+Challenges+Ahead,”+Science+Progress+(2009),+available+at+(last+visited+September+6,+2012).>Google Scholar
29 CFR § 1635.3(g) (emphasis added).Google Scholar